A detailed history of Price T Rowe Associates Inc transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,102,912 shares of IOVA stock, worth $22.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,102,912
Previous 3,482,402 10.9%
Holding current value
$22.9 Million
Previous $27.9 Million 4.33%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.28 - $11.9 $2.76 Million - $4.52 Million
-379,490 Reduced 10.9%
3,102,912 $29.1 Million
Q2 2024

Aug 14, 2024

SELL
$7.78 - $14.19 $13.9 Million - $25.3 Million
-1,785,462 Reduced 33.89%
3,482,402 $27.9 Million
Q1 2024

May 15, 2024

BUY
$7.59 - $17.47 $15.1 Million - $34.8 Million
1,991,262 Added 60.77%
5,267,864 $78.1 Million
Q4 2023

Feb 14, 2024

SELL
$3.3 - $8.89 $1.06 Million - $2.85 Million
-320,518 Reduced 8.91%
3,276,602 $26.6 Million
Q3 2023

Nov 14, 2023

SELL
$4.44 - $8.79 $294,163 - $582,363
-66,253 Reduced 1.81%
3,597,120 $16.4 Million
Q2 2023

Aug 14, 2023

SELL
$5.36 - $9.06 $495,773 - $838,004
-92,495 Reduced 2.46%
3,663,373 $25.8 Million
Q1 2023

May 15, 2023

SELL
$5.53 - $8.22 $513,532 - $763,333
-92,863 Reduced 2.41%
3,755,868 $22.9 Million
Q4 2022

Feb 14, 2023

SELL
$5.62 - $10.0 $4.85 Million - $8.63 Million
-862,583 Reduced 18.31%
3,848,731 $24.6 Million
Q3 2022

Nov 14, 2022

BUY
$9.53 - $13.11 $3.44 Million - $4.73 Million
360,629 Added 8.29%
4,711,314 $45.1 Million
Q2 2022

Aug 15, 2022

SELL
$6.38 - $18.33 $5.14 Million - $14.8 Million
-805,961 Reduced 15.63%
4,350,685 $48 Million
Q1 2022

May 16, 2022

BUY
$12.38 - $19.1 $6.1 Million - $9.41 Million
492,861 Added 10.57%
5,156,646 $85.9 Million
Q4 2021

Feb 14, 2022

BUY
$16.55 - $27.63 $646,393 - $1.08 Million
39,057 Added 0.84%
4,663,785 $89 Million
Q3 2021

Nov 15, 2021

SELL
$20.35 - $26.63 $525,518 - $687,693
-25,824 Reduced 0.56%
4,624,728 $114 Million
Q2 2021

Aug 16, 2021

SELL
$16.33 - $33.07 $7.92 Million - $16 Million
-484,904 Reduced 9.44%
4,650,552 $121 Million
Q1 2021

May 17, 2021

SELL
$28.67 - $52.59 $64.4 Million - $118 Million
-2,246,749 Reduced 30.43%
5,135,456 $163 Million
Q4 2020

Feb 16, 2021

BUY
$28.04 - $50.26 $207 Million - $371 Million
7,382,205 New
7,382,205 $343 Million

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.16B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.